"I
have a strong preference for an external candidate," Woodford
said in an e-mailed statement.
Britain's biggest drugmaker said on Thursday that Witty would
retire at the end of March 2017, after leading the company since
2008, and the board would consider both internal and external
candidates to replace him.
During his time at the helm Witty has struggled with flagging
sales and profits and some investors - most notably Woodford -
have questioned his focus on a consumer health business that
ranges from headache pills to toothpaste.
Woodford has said in the past he would like to see GSK split up
into its constituent parts, with consumer health separated from
the company's core business of developing and selling
prescription drugs.
Woodford Investment Management has a 1.23 percent stake in GSK,
ranking it eighth among investors in the group, according to
latest filings.
(Reporting by Ben Hirschler; editing by Jason Neely)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|